NASDAQ:GALT - Galectin Therapeutics Stock Price, Forecast & News

Galectin Therapeutics trades on the NASDAQ under the ticker symbol "GALT."

Galectin Therapeutics Inc. (NASDAQ:GALT) issued its quarterly earnings results on Tuesday, November, 12th. The company reported ($0.05) EPS for the quarter, beating analysts' consensus estimates of ($0.08) by $0.03. View Galectin Therapeutics' Earnings History.

Galectin Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, March 4th 2020. View Earnings Estimates for Galectin Therapeutics.

1 analysts have issued 12-month price objectives for Galectin Therapeutics' shares. Their forecasts range from $11.00 to $11.00. On average, they anticipate Galectin Therapeutics' share price to reach $11.00 in the next twelve months. This suggests a possible upside of 308.9% from the stock's current price. View Analyst Price Targets for Galectin Therapeutics.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Galectin Therapeutics in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Galectin Therapeutics.

News coverage about GALT stock has trended somewhat negative this week, InfoTrie Sentiment reports. The research group identifies negative and positive media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Galectin Therapeutics earned a coverage optimism score of -1.9 on InfoTrie's scale. They also gave news articles about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for Galectin Therapeutics.

Galectin Therapeutics saw a drop in short interest during the month of January. As of January 31st, there was short interest totalling 4,660,000 shares, a drop of 8.1% from the January 15th total of 5,070,000 shares. Based on an average daily volume of 262,900 shares, the days-to-cover ratio is currently 17.7 days. Approximately 11.4% of the company's stock are sold short. View Galectin Therapeutics' Current Options Chain.

Some companies that are related to Galectin Therapeutics include Molecular Templates (MTEM), XBiotech (XBIT), ZIOPHARM Oncology (ZIOP), Arcus Biosciences (RCUS), AC Immune (ACIU), Ardelyx (ARDX), Puma Biotechnology (PBYI), Assembly Biosciences (ASMB), Crinetics Pharmaceuticals (CRNX), Kura Oncology (KURA), Neoleukin Therapeutics (NLTX), Axovant Sciences (AXON), Catalyst Pharmaceuticals (CPRX), Morphic (MORF) and MacroGenics (MGNX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Galectin Therapeutics investors own include Progenics Pharmaceuticals (PGNX), Viking Therapeutics (VKTX), Exelixis (EXEL), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), Catalyst Pharmaceuticals (CPRX), Novavax (NVAX), Rigel Pharmaceuticals (RIGL), Synergy Pharmaceuticals (SGYP) and Intercept Pharmaceuticals (ICPT).

Galectin Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Advisor Group Inc. (1.41%), State Street Corp (1.18%), Geode Capital Management LLC (0.96%), Cambridge Investment Research Advisors Inc. (0.34%), Virtu Financial LLC (0.10%) and UBS Group AG (0.09%). Company insiders that own Galectin Therapeutics stock include Fund LP 10X, Gilbert F Amelio, Gilbert S Omenn, Harold H Shlevin, Jack W Callicutt, James C Czirr, Joel Lewis, Kary Eldred, Kevin D Freeman, Marc Rubin, Peter G Traber, Richard E Uihlein and Theodore Daniel Zucconi. View Institutional Ownership Trends for Galectin Therapeutics.

GALT stock was sold by a variety of institutional investors in the last quarter, including Cambridge Investment Research Advisors Inc. and Goldman Sachs Group Inc.. Company insiders that have sold Galectin Therapeutics company stock in the last year include Fund LP 10X and Marc Rubin. View Insider Buying and Selling for Galectin Therapeutics.

GALT stock was acquired by a variety of institutional investors in the last quarter, including State Street Corp, Geode Capital Management LLC, Virtu Financial LLC, Renaissance Technologies LLC, Oxford Asset Management LLP, Advisor Group Inc., Barclays PLC and UBS Group AG. Company insiders that have bought Galectin Therapeutics stock in the last two years include Jack W Callicutt, Joel Lewis, Kary Eldred, Kevin D Freeman and Richard E Uihlein. View Insider Buying and Selling for Galectin Therapeutics.

Shares of GALT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of GALT stock can currently be purchased for approximately $2.69.

Galectin Therapeutics has a market capitalization of $153.02 million. The company earns $-13,900,000.00 in net income (profit) each year or ($0.38) on an earnings per share basis. Galectin Therapeutics employs 6 workers across the globe.View Additional Information About Galectin Therapeutics.

The official website for Galectin Therapeutics is http://www.galectintherapeutics.com/.

Galectin Therapeutics' mailing address is 4960 PEACHTREE INDUSTRIAL BLVD. SUITE 240, NORCROSS GA, 30071. The company can be reached via phone at 678-620-3186 or via email at [email protected]